Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial - CNBC

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial  CNBCLilly’s experimental diabetes shot yields record weight loss in study  The Detroit NewsLilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes  Eli LillyEli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial  statnews.comLilly's next-gen obesity drug shows reduction in blood sugar levels in trial  Yahoo Finance